Why PAD Remains a Major Unmet Need
Peripheral artery disease is an atherosclerotic occlusive condition affecting primarily the lower extremity arteries, producing a clinical spectrum that ranges from intermittent claudication to critical limb ischemia (CLI) — the terminal manifestation carrying a poor prognosis, particularly in diabetic patients who face compounded ischemic risk. The disease affects over 200 million people globally, and the subset of CLI patients who are ineligible for surgical or endovascular revascularisation represent a population with essentially no approved disease-modifying options beyond amputation risk management.
Over two decades of research have centred on “therapeutic angiogenesis” — deliberately stimulating new blood vessel formation in ischaemic limb tissue — as a biological alternative to mechanical revascularisation. The strategies pursued include gene therapy encoding angiogenic growth factors, cell-based regenerative approaches, small molecule pharmacology, and most recently, isoform-specific antibody targeting and miRNA modulation. Despite this breadth of activity, no therapeutic angiogenesis agent has achieved Western regulatory approval, creating a persistent gap between preclinical promise and Phase III confirmation according to WHO-recognised cardiovascular disease burden data.
Therapeutic angiogenesis refers to the deliberate induction of new blood vessel formation in ischaemic tissue using biological or pharmacological agents — including gene constructs encoding growth factors, stem cell populations, or small molecules — as an alternative to surgical revascularisation for patients with peripheral artery disease or critical limb ischaemia who are not candidates for standard interventional procedures.
The primary molecular targets identified across retrieved patent and literature evidence include VEGF-A and its isoforms (particularly the pro-angiogenic VEGF165 and the anti-angiogenic splice variant VEGF165b), fibroblast growth factor 4 (FGF4), hepatocyte growth factor (HGF), stromal cell-derived factor 1α (SDF-1α), NADPH oxidase (NOX) isoforms, platelet-derived growth factor (PDGF) subtypes, and the microRNA regulator miR-548j-5p. The nitric oxide pathway — specifically the ADMA-DDAH-eNOS axis — is also frequently cited as a target for endothelial function restoration in ischaemic PAD tissue.
Peripheral artery disease affects over 200 million people globally. Critical limb ischaemia, its terminal manifestation, carries a poor prognosis — particularly in diabetic patients — and represents a major unmet therapeutic need for patients ineligible for surgical or endovascular revascularisation.
The VEGF Axis: From Failed Trials to Isoform-Specific Targeting
The failure of VEGF-A gene therapy in Western Phase III trials is not simply a delivery problem — retrieved research from Augusta University’s Vascular Biology Center identifies a mechanistic culprit: the anti-angiogenic splice variant VEGF165b. Unlike the pro-angiogenic VEGF165, VEGF165b activates VEGFR1 rather than VEGFR2, thereby bypassing the VEGFR2-eNOS-nitric oxide signalling axis that classical angiogenesis requires. In diabetic and eNOS-deficient patients — the very populations most in need of therapeutic angiogenesis — VEGF165b prevalence may actively suppress the angiogenic response to exogenous VEGF-A delivery.
“VEGF165b antibody-mediated neutralisation improved perfusion recovery in three preclinical PAD models — including type-2 diabetic and eNOS-knockout mice — without requiring intact nitric oxide signalling, a potentially paradigm-shifting mechanistic insight for diabetic PAD patients.”
The Augusta University group demonstrated that isoform-specific antibody-mediated neutralisation of VEGF165b restored perfusion in three distinct preclinical PAD models: a type-2 diabetic model, eNOS-knockout mice, and myoglobin transgenic mice. Crucially, the mechanism operates independently of nitric oxide signalling — a recognised barrier to classical VEGF therapies in diabetic and eNOS-deficient patients. This NO-independent mechanism of action is a key differentiation signal for the diabetic CLI subpopulation, where standard VEGF approaches have consistently underperformed.
The only approved gene therapy for PAD in any jurisdiction remains pl-VEGF165 (Neovasculgen), which received regulatory approval in Russia in 2011 for atherosclerotic PAD (Fontaine Stage II–III). A 210-patient postmarketing surveillance study conducted by the Human Stem Cells Institute in Moscow evaluated its safety and efficacy in chronic limb ischaemia. No equivalent gene therapy has received approval from the FDA or EMA, representing a significant regulatory asymmetry and a potential opportunity for sponsors with robust Phase III-enabling data packages.
VEGF165b is an anti-angiogenic splice variant of VEGF-A that activates VEGFR1 rather than VEGFR2, bypassing the VEGFR2-eNOS-nitric oxide signalling axis required for classical angiogenesis. Augusta University researchers demonstrated that antibody-mediated VEGF165b neutralisation improved perfusion recovery in three preclinical PAD models — including type-2 diabetic and eNOS-knockout mice — without requiring intact nitric oxide signalling.
Explore the full VEGF165b patent and literature landscape with PatSnap Eureka’s AI-powered search.
Search PAD Patent Intelligence in PatSnap Eureka →Combination Gene Therapy: Synergism Beyond Single-Factor Delivery
The next generation of PAD gene therapy is moving decisively toward multi-factor constructs, with two distinct combination strategies supported by both commercial IP and preclinical data. Both strategies are predicated on the same core insight: single angiogenic growth factors are insufficient to drive robust, durable neovascularisation in ischaemic tissue, and combining complementary signalling pathways achieves synergism that neither agent achieves alone.
VEGF-A + FGF4: Dual AAV Bicistronic Delivery
Researchers at Jagiellonian University in Kraków demonstrated that co-delivery of VEGF-A and FGF4 via a single AAV bicistronic construct (AAV-FGF4-IRES-VEGF-A) produced significantly superior post-ischaemic blood flow recovery compared to single-gene VEGF-A delivery in murine hindlimb ischaemia models. FGF4 co-expression improved perfusion recovery beyond what VEGF-A alone achieved, positioning dual-factor AAV constructs as a next-generation gene therapy platform. Drug developers should assess freedom-to-operate around bicistronic vector constructs for PAD indications, as this approach is currently represented in the retrieved dataset primarily as academic research rather than commercial IP.
HGF + SDF-1α: Active Commercial IP from ViroMed
The most clearly commercial IP asset in the retrieved dataset is an active European patent (2020) from ViroMed Co., Ltd. (South Korea) covering a pharmaceutical composition combining hepatocyte growth factor (HGF) or its isoform with SDF-1α (or their encoding polynucleotides) for preventing or treating peripheral vascular and ischaemic limb disease. The patent describes the combination as significantly promoting vascular endothelial cell migration and angiogenesis beyond single-agent HGF or SDF-1α use — an IP-differentiated strategy targeting both angiogenesis (via HGF) and endothelial progenitor cell recruitment (via SDF-1α) simultaneously.
ViroMed Co., Ltd. holds an active European patent (2020) for a pharmaceutical composition combining hepatocyte growth factor (HGF) and stromal cell-derived factor 1α (SDF-1α) for peripheral vascular and ischaemic limb disease. The combination was shown to promote vascular endothelial cell migration and angiogenesis beyond what either single agent achieves alone.
The convergence of both academic (VEGF-A + FGF4) and commercial (HGF + SDF-1α) evidence on combination gene therapy as a superior strategy reflects a broader recognition that the ischaemic microenvironment in PAD requires simultaneous stimulation of multiple angiogenic pathways. According to research published through NIH‘s PubMed database, single-growth-factor approaches have consistently underperformed in randomised controlled settings, supporting the scientific rationale for multi-target strategies.
Cell Therapy, Small Molecules, and Emerging Platforms
Beyond gene therapy, the PAD angiogenesis pipeline encompasses cell-based regenerative approaches, repositioned small molecules, nanoparticle delivery systems, and early-stage molecular targets — each occupying a distinct position in the translational landscape from exploratory research to clinical use.
Stem Cell and Endothelial Progenitor Cell Therapy
Cell-based regenerative therapy for PAD has accumulated the most clinical evidence of any non-approved angiogenic modality. A meta-analysis of 13 clinical trials involving 527 PAD patients (mean age 64.2 years, median follow-up 6 months) reported signals of benefit on all-cause mortality, amputation rate, ulcer healing, and ankle-brachial index from stem cell-based therapy. Cell types studied include bone marrow mononuclear cells (BMMNCs), G-CSF-mobilised peripheral blood mononuclear cells, mesenchymal stem cells, and endothelial progenitor cells. A separate systematic review by West China Hospital, Sichuan University, evaluated autologous stem cell implantation versus placebo in “no-option” PAD patients. Despite these signals, individual trial results remain heterogeneous and no Phase III efficacy confirmation has been reported in the retrieved data.
A meta-analysis of 13 clinical trials involving 527 PAD patients (mean age 64.2 years, median follow-up 6 months) reported signals of benefit on all-cause mortality, amputation rate, ulcer healing, and ankle-brachial index from stem cell-based therapy. However, individual trial results remain heterogeneous and no Phase III efficacy confirmation has been reported.
Small Molecules: Bezafibrate, Cilostazol, and Pitavastatin
Retrieved results document three small molecule approaches with pro-angiogenic activity in PAD-relevant models. Bezafibrate, a pan-PPAR agonist, restored angiogenesis and upregulated VEGF and VEGFR-2 in hindlimb ischaemia models in both normal and diabetic rats, increasing capillary density and capillary/fibre ratio in ischaemic tissue. Cilostazol, a phosphodiesterase-3 inhibitor with established clinical use for intermittent claudication, was characterised in a 2022 study from National Cheng Kung University as having pro-angiogenic activity through the adiponectin/adipoR/SIRT1 pathway in diabetic conditions — suggesting a secondary angiogenic benefit beyond its antiplatelet indication. PLGA nanoparticle-mediated delivery of pitavastatin, investigated by Kyushu University, demonstrated therapeutic arteriogenesis and angiogenesis in animal models of hindlimb ischaemia, combining a bioabsorbable delivery platform with an existing small molecule to achieve targeted endothelial cell pro-angiogenic effects.
Emerging Molecular Targets: NOX Isoforms and miR-548j-5p
Two early-stage targets represent potential IP whitespace in the PAD angiogenesis field. NADPH oxidase (NOX) isoforms — particularly NOX2 and NOX4 — were identified by University of Sydney researchers as regulators of endothelial cell angiogenesis through reactive oxygen species generation. NOX isoforms modulate endothelial cell proliferation, migration, and differentiation, suggesting isoform-selective NOX modulation as a plausible adjunctive pro-angiogenic intervention. Separately, a 2022 study from Taipei Veterans General Hospital identified miR-548j-5p as a circulating microRNA regulator of angiogenesis in PAD patient samples, with downstream effects on endothelial progenitor cell function characterised in vitro and in vivo in mouse hindlimb ischaemia models. Neither target appears to have generated substantial patent activity in the retrieved dataset, representing potential first-mover IP opportunities for academic groups and early-stage biotechs.
A 2022 study from Taipei Veterans General Hospital identified miR-548j-5p as a circulating microRNA regulator of angiogenesis in peripheral artery disease patient samples, with downstream effects on endothelial progenitor cell function demonstrated in vitro and in vivo in mouse hindlimb ischaemia models. This target represents an early-stage IP whitespace opportunity in PAD angiogenesis.
Map the full competitive landscape for PAD angiogenesis targets — patents, literature, and assignees — in PatSnap Eureka.
Analyse PAD Pipeline Data in PatSnap Eureka →Strategic Implications for Drug Developers and IP Teams
The PAD therapeutic angiogenesis landscape presents several distinct strategic opportunities, each supported by the retrieved patent and literature evidence. The field is characterised by a high paper-to-patent ratio — innovation activity is predominantly literature-driven and academic — with only two patents retrieved in the dataset, suggesting commercial IP remains relatively sparse relative to the volume of scientific output.
The Diabetic CLI Subpopulation as a Priority Indication
Retrieved results repeatedly highlight that diabetic patients have impaired angiogenic responses due to eNOS uncoupling, oxidative stress, and anti-angiogenic VEGF isoform prevalence. Multiple retrieved modalities — bezafibrate, VEGF165b antibody, low-level laser therapy, and cilostazol — have been specifically tested in diabetic ischaemia models. This subpopulation may warrant a dedicated investigational new drug strategy with clinical endpoints focused on ankle-brachial index improvement, ulcer healing, and amputation-free survival. According to WIPO patent trend data, vascular gene therapy remains an active filing category, reinforcing the commercial relevance of this indication.
Regulatory Asymmetry: The Western Approval Gap
The only approved gene therapy for PAD in any jurisdiction is pl-VEGF165 (Neovasculgen), approved in Russia in 2011. No FDA or EMA approval exists for any therapeutic angiogenesis agent for PAD. This asymmetry represents a regulatory gap and a potential opportunity for sponsors with robust Phase III-enabling data packages targeting Western markets. The PatSnap life sciences intelligence platform enables systematic monitoring of regulatory submission activity and clinical trial registrations in this space.
IP Landscape: Where the Whitespace Lies
The retrieved dataset contains two patents: ViroMed’s active EP patent for HGF + SDF-1α combination (2020) and an inactive 1993 DE patent for defibrotide in peripheral arteriopathies. The scarcity of commercial IP relative to the volume of academic research signals that most mechanistic innovations in this space — VEGF165b antibody targeting, dual AAV gene constructs, NOX isoform modulation, miR-548j-5p antisense strategies — remain open for IP development. Developers should conduct freedom-to-operate assessments around bicistronic AAV vector constructs and isoform-specific anti-VEGF antibody formats, and consider first-mover patent strategies for the emerging miRNA and NOX isoform targets. PatSnap’s patent analytics tools can accelerate this landscape mapping.
The PAD therapeutic angiogenesis patent landscape is sparse relative to the volume of academic literature: only two patents were retrieved in the analysed dataset — ViroMed’s active EP patent (2020) for HGF + SDF-1α combination therapy, and an inactive 1993 DE patent for defibrotide. Most mechanistic innovations, including VEGF165b antibody targeting, dual AAV gene constructs, NOX isoform modulation, and miR-548j-5p strategies, remain open for IP development.